Drug firm Dr Reddy's Laboratories (DRL) today said it has shifted focus of its drug discovery to new segments, including dermatology and pain management, from cardiac diseases and diabetes due to high costs involved for the latter.
"We have now selected areas, which are available for innovation...we moved away from cardiovascular diseases (CVDs) and diabetes towards pain and inflammation, dermatology and of course anti-infectives...," Dr Reddy's Laboratories Vice Chairman and CEO GV Prasad told reporters here.
Some of the trials for CVDs required at least 30,000 patients which the company could not afford, he added.
When asked about the new drugs being developed, Prasad said that the company is looking at a product which will address the post surgical infectives.
"We are looking at a product which will directly address this segment of post surgical infections," Prasad said.
The Hyderabad-based firm, which had revenues of USD 1.7 billion in FY 11, said it is looking to improve its performance in India and Europe.
"We would like to improve our performance in Europe and India. In India, the issue is growth while in Europe it is profitability. We are working on that," he added.
The company said that it is looking at biosimilars as major area of growth for the firm from 2016 to 2020.
Shares of Dr Reddy's Laboratories were today trading at Rs 1,584.05 in the afternoon trade on BSE, down 1.38 per cent from its previous close.
"We have now selected areas, which are available for innovation...we moved away from cardiovascular diseases (CVDs) and diabetes towards pain and inflammation, dermatology and of course anti-infectives...," Dr Reddy's Laboratories Vice Chairman and CEO GV Prasad told reporters here.
Some of the trials for CVDs required at least 30,000 patients which the company could not afford, he added.
When asked about the new drugs being developed, Prasad said that the company is looking at a product which will address the post surgical infectives.
"We are looking at a product which will directly address this segment of post surgical infections," Prasad said.
The Hyderabad-based firm, which had revenues of USD 1.7 billion in FY 11, said it is looking to improve its performance in India and Europe.
"We would like to improve our performance in Europe and India. In India, the issue is growth while in Europe it is profitability. We are working on that," he added.
The company said that it is looking at biosimilars as major area of growth for the firm from 2016 to 2020.
Shares of Dr Reddy's Laboratories were today trading at Rs 1,584.05 in the afternoon trade on BSE, down 1.38 per cent from its previous close.
No comments:
Post a Comment